Epix Pharmaceuticals Inc. announced that results from a Phase IIa clinical trial of EP-2104R found that the imaging agent was able to detect blood clots not previously seen on MRI and enhanced images previously seen.
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now